Exon Skipping Using Antisense Oligonucleotides for Laminin-Alpha2-Deficient Muscular Dystrophy

Area of Science:

• Biochemistry
• Genetics
• Molecular Biology

Background:

• Phosphorodiamidate morpholino oligomers (PMOs) are a promising therapeutic strategy for neuromuscular disorders like Duchenne muscular dystrophy.
• A key limitation is the inefficient and inconsistent delivery of PMOs into muscle fibers, with the underlying mechanism unclear.

Purpose of the Study:

• To investigate the mechanism of PMO uptake by muscle fibers.
• To evaluate the therapeutic efficacy of PMO-mediated exon skipping in a mouse model of merosin-deficient congenital muscular dystrophy 1A (MDC1A).

Main Methods:

• Utilized wild-type and dystrophic mdx52 mice to study PMO uptake during myogenesis.
• Employed in situ hybridization to detect PMO localization in regenerating fibers.
• Administered PMO therapy to laminin-alpha2 chain-null dy^3K/dy^3K mice, a model of MDC1A, to assess exon skipping and therapeutic outcomes.

Main Results:

• PMO uptake was significantly higher in muscle fibers during myotube formation.
• PMOs were predominantly found in embryonic myosin heavy chain-positive regenerating fibers.
• Exon skipping in dy^3K/dy^3K mice led to laminin-alpha2 chain recovery and a slight increase in lifespan.

Conclusions:

• Muscle fiber uptake of PMOs is dependent on the developmental stage of myogenesis, not solely on dystrophin-deficient membranes.
• PMO-mediated exon skipping demonstrates therapeutic potential in MDC1A models with active muscle regeneration.
• These findings provide a basis for developing PMO-based therapies for muscular disorders characterized by regeneration.